Valuation: Shield Therapeutics plc

Market Cap 50.29M 68.6M 58.79M 55M 94.89M 6.57B 95.9M 651M 253M 3.3B 258M 252M 10.91B P/E 2026 *
-214x
P/E 2027 * 6.37x
Enterprise Value 68.35M 93.25M 79.91M 74.76M 129M 8.93B 130M 885M 344M 4.48B 350M 343M 14.83B EV / Sales 2026 *
1.23x
EV / Sales 2027 * 0.82x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -
1 day+2.98%
1 week+10.00%
Current month+22.53%
1 month-15.09%
3 months-17.41%
6 months-51.60%
Current year-50.86%
1 week 4.3
Extreme 4.3
5.2
1 month 3.7
Extreme 3.7
6.3
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Investor Relations Contact - -
General Counsel - 01/01/2026
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap.
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/2/25 Free

Chief Executive Officer

5,000,000 0.4800%
13/2/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+2.98%+10.00%-35.47%-50.36% 68.6M
-0.66%+2.80%+40.55%-0.33% 82.73B
-4.30%+115.47%+412.13%+23.29% 55.45B
+2.68%+10.02%-19.76%-34.08% 57.94B
+1.42%+1.61%-0.67%+34.08% 52.57B
+0.50%+1.66%+9.90%+170.45% 48.94B
+0.62%+4.29%+56.57%-16.88% 32.23B
+0.13%+3.63%+50.49%+99.25% 25.94B
+0.50%+3.47%+0.05%+195.86% 22.1B
+0.88%-1.89%+57.06%+105.87% 16.55B
Average +0.47%+16.66%+57.09%+52.72% 39.45B
Weighted average by Cap. +0.02%+21.99%+75.00%+44.44%

Financials

2026 *2027 *
Net sales 55.38M 75.55M 64.75M 60.57M 105M 7.23B 106M 717M 279M 3.63B 284M 278M 12.02B 74.75M 102M 87.4M 81.76M 141M 9.77B 143M 968M 376M 4.9B 383M 375M 16.22B
Net income -74.5K -102K -87.11K -81.49K -141K -9.73M -142K -964K -375K -4.89M -382K -373K -16.17M 7.86M 10.72M 9.19M 8.6M 14.83M 1.03B 14.99M 102M 39.56M 516M 40.27M 39.39M 1.71B
Net Debt 18.06M 24.64M 21.12M 19.76M 34.09M 2.36B 34.45M 234M 90.91M 1.18B 92.53M 90.53M 3.92B 10.96M 14.95M 12.81M 11.99M 20.68M 1.43B 20.9M 142M 55.15M 719M 56.14M 54.92M 2.38B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
25/08/26 GBX 4.840 +2.98% 1,033
24/08/26 GBX 4.700 -3.09% 1,429,474
21/08/26 GBX 4.850 -1.02% 1,738,484
20/08/26 GBX 4.900 +11.36% 8,085,372
19/08/26 GBX 4.400 0.00% 436,423
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0470GBP
Average target price
0.1667GBP
Spread / Average Target
+254.62%

Annual profits - Rate of surprise